Bristol Myers Squibb gets priority review for AML drug as list of potential Celgene hits lengthens
Potential approvals keep emerging out of Celgene’s old lineup.
Today, the FDA accepted and gave priority review to CC-486, an acute myeloid leukemia drug that made a splash in December at ASH when Phase III data showed patients taking the drug lived just under 10 months longer than patients taking placebo, a major advance in what has remained one of the most intractable blood cancers.
The priority review adds to the growing body of evidence Bristol Myers Squibb can point to in defense of their $74 billion acquisition of Celgene, which attracted criticism not only from consumer groups with anti-trust concerns but also from investors who questioned whether the thalidomide-repurposing behemoth still had a deep enough pipeline to justify the cost.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 129,300+ biopharma pros reading Endpoints daily — and it's free.